Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
EV-to-FCF is calculated as enterprise value divided by its free cash flow. As of today, Affimed NV's Enterprise Value is $-13.70 Mil.
Affimed NV's Free Cash Flow for the trailing twelve months (TTM) ended in Sep. 2024 was $-84.35 Mil. Therefore, Affimed NV's EV-to-FCF for today is 0.16.
The historical rank and industry rank for Affimed NV's EV-to-FCF or its related term are showing as below:
AFMDQ'
s EV-to-FCF Range Over the Past 10 Years
Min: 0 Med: 0 Max: 0.16
Current: 0.16
During the past 12 years, the highest EV-to-FCF of Affimed NV was 0.16. The lowest was 0.00. And the median was 0.00.
AFMDQ's EV-to-FCF is not ranked
in the Biotechnology industry.
Industry Median: 14.31
vs AFMDQ: 0.16
EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
Affimed NV's share price for today is $0.0001.
Affimed NV's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Sep. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $-4.982.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Enterprise Value is used because it is a more complete measure in reflecting how much an investor pays when buying a company. Free Cash Flow is an important financial metric because it represents the actual amount of cash at a company's disposal. Companies with a low EV-to-FCF ratio, combined with a strong balance sheet are generally considered as undervalued.
Affimed NV EV-to-FCF Related Terms
Affimed NV EV-to-FCF Historical Data
* Premium members only.
The historical data trend for Affimed NV's EV-to-FCF can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Biotechnology subindustry, Affimed NV's EV-to-FCF, along with its competitors' market caps and EV-to-FCF data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Affimed NV EV-to-FCF vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Affimed NV's EV-to-FCF distribution charts can be found below:
* The bar in red indicates where Affimed NV's EV-to-FCF falls into.
Affimed NV's current Enterprise Value is $-13.70 Mil.
Affimed NV's Free Cash Flow for the trailing twelve months (TTM) ended in Sep. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $-84.35 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Affimed NV (AFMDQ) has a EV-to-FCF of 0.16 as of Jul. 30, 2026. EV to FCF ratio is the company's enterprise value divided by free cash flow. View historical data on Affimed NV and its competitors.
Is Affimed NV's EV-to-FCF too high?
Affimed NV's current EV-to-FCF is 0.16. The Biotechnology industry median EV-to-FCF is 14.31. Affimed NV's value of 0.16 is 98.9% below this industry median. Overall, Affimed NV has a GF Score™ of 16/100, reflecting its overall financial health beyond just this single metric.
How does Affimed NV's EV-to-FCF compare to SYRS and BTAX?
Affimed NV's EV-to-FCF of 0.16 can be compared against companies in the Biotechnology industry. The industry median EV-to-FCF is 14.31. Affimed NV's value of 0.16 is 98.9% below this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-FCF for a Biotechnology company?
The median EV-to-FCF among Biotechnology companies is 14.31, based on 346 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-FCF significantly above this median, while those in the bottom quartile fall well below. However, EV-to-FCF should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Affimed NV's current EV-to-FCF of 0.16 is 98.9% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-FCF mean?
A high EV-to-FCF can signal that a stock is expensive relative to its fundamentals. EV to FCF ratio is the company's enterprise value divided by free cash flow. View historical data on Affimed NV and its competitors. For the Biotechnology industry, the median EV-to-FCF is 14.31 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Affimed NV's current EV-to-FCF is 0.16. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Affimed NV stock overvalued right now?
Affimed NV (AFMDQ) has a current EV-to-FCF of 0.16. The current EV-to-FCF is 0.16 and 98.9% below the Biotechnology industry median of 14.31. Affimed NV's overall GF Score™ is 16/100. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-FCF calculated?
EV-to-FCF is calculated from a company's financial statements. For Affimed NV (AFMDQ), the current EV-to-FCF is 0.16 as of Jul. 30, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Affimed NV is a clinical-stage biopharmaceutical company. The company is engaged in discovering and developing targeted cancer immunotherapies. Its product candidates are being developed in the field of immuno-oncology, which represents an approach to cancer treatment that seeks to harness the body's immune defenses to fight tumor cells. It is active in the discovery, pre-clinical and clinical development of antibodies based on its core technology. The company generates revenues from the provision of research and development services to third parties based on both Group and third party owned intellectual property. Geographically, it derives a majority of revenue from the United States and also has a presence in and Germany.
16GF Score
Get the complete analysis for AFMDQ
EV-to-FCF is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
AFMDQ has been successfully added to your 
